Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.1K
Overview
51.1K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.2K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.2K
Cancer Vaccines01:30

Cancer Vaccines

929
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
929
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

2.8K
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
2.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

1.6K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Virus-inspired functional spherical biomaterials constructed from high-symmetry biomacromolecules: design and applications.

Chemical Society reviews·2026
Same author

From microtissues to macro solutions - The future of scalable and automated cartilage tissue engineering.

Journal of orthopaedic translation·2026
Same author

Mechanical Tuning of the Cell Microenvironment Using a Biomimetic Hydrogel System for Articular Cartilage Tissue Engineering.

Journal of tissue engineering and regenerative medicine·2026
Same author

Efficacy of the spring distraction system for different etiologies of early onset scoliosis: evaluating an evolving treatment concept.

Spine deformity·2026
Same author

Cytoskeleton Spotlight: Hiroshi Inaba, PhD.

Cytoskeleton (Hoboken, N.J.)·2026
Same author

A Decade of Leadership and Impact: Celebrating 10 Years of the ORS Spine Section.

JOR spine·2026

Related Experiment Video

Updated: Jan 8, 2026

Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination
06:02

Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination

Published on: February 23, 2024

1.2K

Programmable Antigen-Specific Immunity via Self-Adjuvanting Nanovaccines Co-Delivering Immune Modulators.

Keita Ito1, Yoshiyuki Manabe1,2, Shino Ohshima3

  • 1Department of Chemistry, Graduate School of Science, The University of Osaka, 1-1 Machikaneyama, Toyonaka, Osaka, 560-0043, Japan.

Angewandte Chemie (International Ed. in English)
|December 17, 2025
PubMed
Summary

This study presents a novel self-adjuvanting cancer vaccine platform using peptide antigens conjugated with adjuvants in cationic lipid nanoparticles (LNPs). The enhanced vaccine formulation boosts immunogenicity and precisely modulates immune responses, showing promise for cancer treatment.

Keywords:
AdjuvantDrug delivery systemLipid NanoparticleVaccine

More Related Videos

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection

Published on: September 1, 2023

2.3K
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

13.7K

Related Experiment Videos

Last Updated: Jan 8, 2026

Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination
06:02

Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination

Published on: February 23, 2024

1.2K
Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection

Published on: September 1, 2023

2.3K
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

13.7K

Area of Science:

  • Vaccinology
  • Immunology
  • Nanotechnology

Background:

  • Cancer peptide vaccines aim to stimulate host immunity against tumors but face challenges due to limited antigen immunogenicity.
  • Enhancing peptide antigen potency is crucial for effective cancer vaccine development, particularly for metastatic disease and recurrence prevention.
  • Self-adjuvanting vaccines, created by conjugating antigens with adjuvants, offer a promising strategy to overcome these limitations.

Purpose of the Study:

  • To develop an improved self-adjuvanting vaccine platform by conjugating the antigenic CH401 peptide with the adjuvant Pam3CSK4.
  • To formulate these conjugates into cationic lipid nanoparticles (LNPs) smaller than 100 nm for enhanced immune cell uptake.
  • To investigate the potential of supplemental adjuvants for modulating immune responses within the LNP formulation.

Main Methods:

  • Conjugation of the CH401 peptide antigen with the Pam3CSK4 adjuvant.
  • Formulation of antigen-adjuvant conjugates into cationic lipid nanoparticles (LNPs) using a microflow device (iLiNP) for precise size control (<100 nm).
  • Incorporation of supplemental adjuvants to modulate immune responses.
  • Evaluation of vaccine immunogenicity and immune response modulation in humanized mouse models.

Main Results:

  • The developed vaccine candidates demonstrated significantly enhanced immunogenicity compared to conventional approaches.
  • The platform enabled precise, antigen-specific modulation of immune responses.
  • The cationic lipid nanoparticles facilitated efficient uptake by immune cells.
  • Potent immune responses were successfully elicited in humanized mouse models.

Conclusions:

  • This strategy represents a next-generation self-adjuvanting vaccine platform.
  • The platform effectively enhances and fine-tunes antigen-specific immune responses.
  • This innovative approach holds significant promise for the development of advanced cancer vaccines.